Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin’s Lymphoma and Role of β2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China

Table 4

All-grade AEs.

Toxicities during BR	Major AEs (%)	Grade 3-4 AEs (%)
Nausea and emesis	3 (4.1)	1 (1.4)
Leukopenia	6 (8.2)	5 (6.8)
Fatigue	4 (5.5)
Infections	4 (5.5)
Fever	3 (4.1)
Rash	1 (1.4)

: Major AEs include any grade of adverse events.